Skip to search formSkip to main contentSkip to account menu

ZK-EPO

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
BACKGROUND Sagopilone (ZK-EPO) is a fully synthetic microtubule-stabilizing agent that has demonstrated high antitumor activity… 
Review
2010
Review
2010
  • E. Rivera
  • American journal of clinical oncology
  • 2010
  • Corpus ID: 22323943
Resistance to chemotherapeutic agents is a significant obstacle to the effective treatment of metastatic breast cancer (MBC… 
2009
2009
It has been demonstrated that sagopilone (ZK-EPO) has antitumor activity in human orthotopic glioma models in vitro and in vivo… 
Review
2008
Review
2008
Background: Tubulin is among the most established and clinically validated targets in oncology. The taxanes, paclitaxel and… 
Review
2008
Review
2008
BACKGROUND Tubulin is among the most established and clinically validated targets in oncology. The taxanes, paclitaxel and… 
Highly Cited
2008
Highly Cited
2008
Sagopilone (ZK-EPO) is the first fully synthetic epothilone undergoing clinical trials for the treatment of human tumors. Here… 
2008
2008
5141 Background: The microtubule stabilizer docetaxel, in combination with prednisone, prolongs life in patients with metastatic… 
2008
2008
19081 Background: Sagopilone, a novel epothilone, has shown preclinical activity against SCLC cell lines. A completed Phase I… 
2008
2008
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the…